Scilex Holding Company Common Stock

SCLXNASDAQUSD
8.70 USD
1.74 (25.22%)🔴AT CLOSE (AS OF 08:01 PM EDT)
🔴Market: CLOSED
Open?$7.10
High?$8.84
Low?$6.75
Prev. Close?$6.90
Volume?193.0K
Avg. Volume?40.5K
VWAP?$8.04
Rel. Volume?4.76x
Bid / Ask
Bid?$8.13 × 200
Ask?$8.50 × 100
Spread?$0.37
Midpoint?$8.32
Valuation & Ratios
Market Cap?48.5M
Shares Out?8.5M
Float?5.7M
Float %?66.9%
P/E Ratio?N/A
P/B Ratio?-0.23
EPS?-$57.23
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?0.08Weak
Quick Ratio?0.07Weak
Cash Ratio?0.01Low
Debt/Equity?-0.53Low
ValuationATTRACTIVELY VALUED
Score
93/100
P/E?
N/A
P/B?
-0.23CHEAP
P/S?
1.60CHEAP
P/FCF?
13.2CHEAP
EV/EBITDA?
-0.6CHEAP
EV/Sales?
5.05FAIR
Returns & Efficiency
ROE?
193.7%STRONG
ROA?
-110.3%WEAK
Cash Flow & Enterprise
FCF?$3.7M
Enterprise Value?$152.8M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Employees
34
Market Cap
48.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2022-11-11
Address
960 SAN ANTONIO ROAD
PALO ALTO, CA 94303
Phone: (650) 516-4310